TRTMNT W/LAMIVUDINE+STAVUDINE+ABACAVIR+AMPRENAVIR/RITONAVIR W/SUPV INTERRUPTION

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究旨在了解在艾滋病毒感染的早期阶段联合使用五种抗艾滋病毒药物是否会使血液和某些身体组织中的艾滋病毒无法被检测到，以及即使你停止服用这些药物，病毒是否仍会被检测到。 本研究将使用拉米夫定(3TC，Epivir)、司他夫定(d4T，Zerit？)、阿巴卡韦(ABC，1592U89，Ziagen？)、利托那韦(RTV，Norvir？)和阿普瑞那韦(APV，141W94，AGenerase？)。也可以使用地达诺辛(DDI，Videx)和奈非那韦(NFV，Viracept)。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is designed to see if using a combination of five anti?HIV drugs during the early stage of HIV infection can make the HIV virus in the blood and in certain body tissues undetectable, and whether the virus will stay undetectable even after you stop taking these drugs. This study will use lamivudine (3TC, Epivir¿), stavudine (d4T, Zerit¿), abacavir (ABC, 1592U89, Ziagen¿), ritonavir (RTV, Norvir¿), and amprenavir (APV, 141W94, Agenerase¿). Didanosine (ddI, Videx¿) and nelfinavir (NFV, Viracept¿) may also be used.